Accumulating evidence supports the use of some antidiabetic agents, such as pioglitazone and glucagon-like peptide-1 receptor agonists (GLP-1RAs), to improve histological findings of NASH and fibrosis in T2DM patients [11]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.